{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:59:57Z","timestamp":1790938797313,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05245-y","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:44:45Z","timestamp":1787309085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic performance of FIB-6 for identifying FibroScan-defined advanced fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a cross-sectional diagnostic accuracy study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hossein","family":"Bagheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-6029","authenticated-orcid":false,"given":"Niloofar","family":"Seighali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Sadra","family":"Gholami-Chahkand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Bakhtiyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3137-8054","authenticated-orcid":false,"given":"Fateme","family":"Seighali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Jodeiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-4315","authenticated-orcid":false,"given":"Mohsen","family":"Rajabnia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"issue":"6","key":"5245_CR1","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966\u201386.","journal-title":"Hepatology"},{"issue":"4","key":"5245_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"4","key":"5245_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/liv.15852","volume":"44","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Paik J, Owrangi S, Yilmaz Y, El-Kassas M, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024;44(4):1061\u201370.","journal-title":"Liver Int"},{"issue":"10440","key":"5245_CR4","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"Global incidence","year":"2024","unstructured":"Global incidence. prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133\u201361.","journal-title":"Lancet"},{"issue":"10440","key":"5245_CR5","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"Global burden and strength of evidence for","year":"2024","unstructured":"Global burden and strength of evidence for. 88 risk factors in 204 countries and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2162\u2013203.","journal-title":"Lancet"},{"issue":"1","key":"5245_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"suppl","key":"5245_CR7","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","volume":"29","author":"SK Han","year":"2023","unstructured":"Han SK, Baik SK, Kim MY. Non-alcoholic fatty liver disease: Definition and subtypes. Clin Mol Hepatol. 2023;29(suppl):S5\u201316.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"5245_CR8","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","volume":"103","author":"I Pierantonelli","year":"2019","unstructured":"Pierantonelli I, Svegliati-Baroni G. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Transplantation. 2019;103(1):e1\u201313.","journal-title":"Transplantation"},{"key":"5245_CR9","doi-asserted-by":"publisher","first-page":"101833","DOI":"10.1016\/j.arr.2022.101833","volume":"84","author":"Y He","year":"2023","unstructured":"He Y, Su Y, Duan C, Wang S, He W, Zhang Y, et al. Emerging role of aging in the progression of NAFLD to HCC. Ageing Res Rev. 2023;84:101833.","journal-title":"Ageing Res Rev"},{"key":"5245_CR10","doi-asserted-by":"publisher","unstructured":"Younossi ZM, Stepanova M, Al Shabeeb R, Eberly KE, Shah D, Nguyen V, Ong J, Henry L, Alqahtani SA. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease. Hepatol Commun. 2023;8(1):e0352. https:\/\/doi.org\/10.1097\/HC9.0000000000000352. PMID: 38126928; PMCID: PMC10749707","DOI":"10.1097\/HC9.0000000000000352"},{"issue":"11","key":"5245_CR11","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1007\/s00125-024-06196-3","volume":"67","author":"EASL-EASD-EASO Clinical","year":"2024","unstructured":"EASL-EASD-EASO Clinical. Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary. Diabetologia. 2024;67(11):2375\u201392.","journal-title":"Diabetologia"},{"issue":"5","key":"5245_CR12","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797\u2013835.","journal-title":"Hepatology"},{"issue":"1","key":"5245_CR13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","volume":"151","author":"NWS Chew","year":"2025","unstructured":"Chew NWS, Mehta A, Goh RSJ, Zhang A, Chen Y, Chong B, et al. Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach. Circulation. 2025;151(1):98\u2013119.","journal-title":"Circulation"},{"issue":"2","key":"5245_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","volume":"155","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. Gastroenterology. 2018;155(2):443\u2013e5717.","journal-title":"Gastroenterology"},{"issue":"17","key":"5245_CR15","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559\u201369.","journal-title":"N Engl J Med"},{"issue":"8","key":"5245_CR16","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","volume":"21","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Castera L, Wong VW. Noninvasive Assessment of Liver Fibrosis in NAFLD. Clin Gastroenterol Hepatol. 2023;21(8):2026\u201339.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"18","key":"5245_CR17","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/jama.2023.5997","volume":"329","author":"EB Tapper","year":"2023","unstructured":"Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review. JAMA. 2023;329(18):1589\u2013602.","journal-title":"JAMA"},{"issue":"5","key":"5245_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"K Cusi","year":"2022","unstructured":"Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528\u201362.","journal-title":"Endocr Pract"},{"key":"5245_CR19","doi-asserted-by":"publisher","first-page":"175628482412763","DOI":"10.1177\/17562848241276334","volume":"17","author":"D Hudson","year":"2024","unstructured":"Hudson D, Afzaal T, Bualbanat H, AlRamdan R, Howarth N, Parthasarathy P, et al. Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: the progressive shift from liver biopsy to noninvasive techniques. Ther Adv Gastroenterol. 2024;17:17562848241276334.","journal-title":"Ther Adv Gastroenterol"},{"issue":"Suppl","key":"5245_CR20","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.3350\/cmh.2022.0362","volume":"29","author":"SB Ahn","year":"2023","unstructured":"Ahn SB. Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: current and future developments. Clin Mol Hepatol. 2023;29(Suppl):S150.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"5245_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/hepr.13729","volume":"52","author":"G Shiha","year":"2022","unstructured":"Shiha G, Soliman R, Mikhail NNH, Alswat K, Abdo A, Sanai F, et al. Development and multicenter validation of FIB-6: A novel, machine learning, simple bedside score to rule out liver cirrhosis and compensated advanced chronic liver disease in patients with chronic hepatitis C. Hepatol Res. 2022;52(2):165\u201375.","journal-title":"Hepatol Res"},{"issue":"2","key":"5245_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s00535-022-01932-1","volume":"58","author":"Y Kamada","year":"2023","unstructured":"Kamada Y, Nakamura T, Isobe S, Hosono K, Suama Y, Ohtakaki Y, et al. SWOT analysis of noninvasive tests for diagnosing NAFLD with severe fibrosis: an expert review by the JANIT Forum. J Gastroenterol. 2023;58(2):79\u201397.","journal-title":"J Gastroenterol"},{"issue":"3","key":"5245_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.4103\/sjg.sjg_27_24","volume":"30","author":"K Alswat","year":"2024","unstructured":"Alswat K, Soliman R, Mikhail NNH, \u00d6rmeci N, Dalekos GN, Derbala MFM, et al. Validation of FIB-6 score in assessment of liver fibrosis in chronic hepatitis B. Saudi J Gastroenterol. 2024;30(3):138\u201344.","journal-title":"Saudi J Gastroenterol"},{"key":"5245_CR24","doi-asserted-by":"publisher","unstructured":"Assempoor R, Jodeiri F, Javadi M, Seighali N, Shenava SAS, Najafi K, Antoun I, Hassanabad AF, Kuno T, Biering-S\u00f8rensen T, Hernandez AV, Nelson JR, Hosseini K. Association of the C-reactive protein-triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study. Cardiovasc Diabetol. 2026;25(1):162. https:\/\/doi.org\/10.1186\/s12933-026-03163-7. PMID: 41923130; PMCID: PMC13195924.","DOI":"10.1186\/s12933-026-03163-7"},{"key":"5245_CR25","doi-asserted-by":"publisher","first-page":"h5527","DOI":"10.1136\/bmj.h5527","volume":"351","author":"PM Bossuyt","year":"2015","unstructured":"Bossuyt PM, Reitsma JB, Bruns DE, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. https:\/\/doi.org\/10.1136\/bmj.h5527.","journal-title":"BMJ"},{"issue":"7","key":"5245_CR26","doi-asserted-by":"publisher","first-page":"e38346","DOI":"10.5812\/hepatmon.38346","volume":"16","author":"HI Fallatah","year":"2016","unstructured":"Fallatah HI, Akbar HO, Fallatah AM. Fibroscan Compared to FIB-4, APRI, and AST\/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease. Hepat Mon. 2016;16(7):e38346.","journal-title":"Hepat Mon"},{"issue":"12","key":"5245_CR27","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1111\/liv.16085","volume":"44","author":"L Mart\u00ednez-Arenas","year":"2024","unstructured":"Mart\u00ednez-Arenas L, Vinaixa C, Conde I, Lorente S, D\u00edaz-Fontenla F, Marques P, et al. FibroScan compared to liver biopsy for accurately staging recurrent hepatic steatosis and fibrosis after transplantation for MASH. Liver Int. 2024;44(12):3174\u201382.","journal-title":"Liver Int"},{"issue":"6","key":"5245_CR28","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","volume":"76","author":"QM Anstee","year":"2022","unstructured":"Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol. 2022;76(6):1362\u201378.","journal-title":"J Hepatol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05245-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05245-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05245-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:40:42Z","timestamp":1790937642000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05245-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5245"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05245-y","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"28 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from the ethics committee of Alborz University of Medical Sciences (approval code: IR.ABZUMS.REC.1405.125).All participants received and signed written informed consent before their data were included in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"608"}}